title: Inhibition of tumor necrosis factor alpha by an adenovirus-encoded soluble fusion protein extends transgene expression in the liver and lung.
abstract: The cellular and humoral immune responses to adenovirus (Ad) remain a major barrier to Ad-mediated gene therapy. We recently reported that mice deficient in tumor necrosis factor alpha (TNF-alpha) or Fas (APO-1, CD95) have prolonged expression of an Ad transgene expressing a foreign protein in the liver. To determine whether blockade of TNF-alpha or Fas would have the same effect in normal mice, we created transgenes that expressed soluble murine CD8 or CD8 fused to the extracellular regions of TNF receptor 1 (TNFR) or Fas and inserted into the left-end region of first-generation (E1/E3-) Ad vectors. Consistent with the results observed in TNF-deficient mice, expression of the TNFR-CD8 fusion protein was prolonged in vivo compared to that of control proteins. Not only did expression of TNFR-CD8 persist in the liver and the lung, but when coadministered with another first-generation vector, the protein provided "transprotection" for the companion vector and transgene. In addition, TNFR-CD8 attenuated the humoral immune response to the Ad. Together, these findings demonstrate that blockade of TNF-alpha is likely to be useful in extending the expression of an Ad-encoded transgene in a gene therapy application.
authors.affiliation: Hospital for Special Surgery, Cornell University Medical Center, New York, New York 10021, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Peng
authors.forename: J
authors.initials: J
authors.lastname: Trevejo
authors.forename: J
authors.initials: J
authors.lastname: Zhou
authors.forename: M W
authors.initials: MW
authors.lastname: Marino
authors.forename: R G
authors.initials: RG
authors.lastname: Crystal
authors.forename: E
authors.initials: E
authors.lastname: Falck-Pedersen
authors.forename: K B
authors.initials: KB
authors.lastname: Elkon
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D015703:Antigens, CD / Q000502:physiology; D016827:CD8 Antigens / Q000502:physiology; D004797:Enzyme-Linked Immunosorbent Assay; D015316:Genetic Therapy; D008099:Liver / Q000378:metabolism*; D008168:Lung / Q000378:metabolism*; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D016513:Mice, SCID; D018124:Receptors, Tumor Necrosis Factor / Q000502:physiology; D047888:Receptors, Tumor Necrosis Factor, Type I; D011993:Recombinant Fusion Proteins / Q000494:pharmacology*; D019076:Transgenes; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D019014:fas Receptor / Q000502:physiology
chemical_list: D000914:Antibodies, Viral; D015703:Antigens, CD; D016827:CD8 Antigens; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; D019014:fas Receptor